4.7 Article

Uncovering molecular elements of brain-body communication during development and treatment of neuropathic pain

期刊

BRAIN BEHAVIOR AND IMMUNITY
卷 21, 期 1, 页码 112-124

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbi.2006.06.001

关键词

neuropathic pain; tumor necrosis factor; chronic constriction injury; hyperalgesia; alpha(2)-adrenergic receptor; cyclic adenosine monophosphate (cAMP); hippocampus; sciatic nerve; rat

资金

  1. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041352] Funding Source: NIH RePORTER
  2. NINDS NIH HHS [NS41352] Funding Source: Medline

向作者/读者索取更多资源

Integral to neuropathic pain is a reciprocal interaction between tumor necrosis factor-alpha (TNF) production and the alpha(2)-adrenergic receptor response, offering an attractive therapeutic target. The effects of varying levels of brain TNF on alpha(2)-adrenergic regulation of cyclic AMP (cAMP) production in the hippocampus and sciatic nerve were investigated during the development and amitriptyline treatment of chronic pain. Increased levels of TNF during the development of chronic pain transform alpha(2)-adrenergic inhibition of cAMP production in the brain to potentiation. While alpha(2)-adrenergic receptors regulate TNF production, they also affect descending noradrenergic pathways. Increases in levels of TNF in the brain deeply impact peripheral inflammation through regulating alpha(2)-adrenergic receptors, offering insight into brain-body interactions during neuropathic pain. Amitriptyline as an analgesic inhibits pain-induced increases in brain-associated TNF and transforms peripheral alpha(2)-adrenergic receptors. The dynamic equilibrium between TNF levels and alpha(2)-adrenergic functioning is uniquely altered during development and treatment of neuropathic pain. Proper manipulations of this interaction offer efficacious treatment of neuropathic pain. (c) 2006 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据